Sarepta Therapeutics Inc (NASDAQ:SRPT) has received a consensus rating of “Buy” from the twenty-eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, twenty-three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $185.60.
A number of equities research analysts recently commented on the stock. Citigroup raised their price objective on shares of Sarepta Therapeutics from $174.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday. BidaskClub lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 31st. Piper Jaffray Companies dropped their price objective on shares of Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating on the stock in a report on Friday, October 26th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $147.00 price objective on the stock in a report on Tuesday, October 16th. Finally, Sanford C. Bernstein assumed coverage on shares of Sarepta Therapeutics in a report on Friday, October 12th. They set an “outperform” rating and a $170.00 price objective on the stock.
Shares of NASDAQ:SRPT opened at $137.18 on Friday. Sarepta Therapeutics has a 12 month low of $50.51 and a 12 month high of $176.50. The company has a current ratio of 8.85, a quick ratio of 7.84 and a debt-to-equity ratio of 0.65. The firm has a market cap of $9.75 billion, a P/E ratio of -83.65 and a beta of 1.59.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.29). Sarepta Therapeutics had a negative return on equity of 23.67% and a negative net margin of 89.46%. The company had revenue of $78.49 million for the quarter, compared to analyst estimates of $78.84 million. Research analysts predict that Sarepta Therapeutics will post -4.38 earnings per share for the current fiscal year.
In other news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $140.50, for a total value of $936,713.50. Following the completion of the transaction, the director now owns 126,534 shares of the company’s stock, valued at approximately $17,778,027. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sandesh Mahatme sold 107,524 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, October 24th. The shares were sold at an average price of $127.74, for a total transaction of $13,735,115.76. Following the completion of the transaction, the chief financial officer now directly owns 48,381 shares of the company’s stock, valued at approximately $6,180,188.94. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC grew its position in shares of Sarepta Therapeutics by 0.9% in the 2nd quarter. FMR LLC now owns 9,749,879 shares of the biotechnology company’s stock valued at $1,288,739,000 after acquiring an additional 82,453 shares during the period. RTW Investments LP boosted its holdings in shares of Sarepta Therapeutics by 42.2% during the 2nd quarter. RTW Investments LP now owns 978,551 shares of the biotechnology company’s stock worth $129,345,000 after buying an additional 290,280 shares during the period. Millennium Management LLC boosted its holdings in shares of Sarepta Therapeutics by 242.2% during the 2nd quarter. Millennium Management LLC now owns 858,407 shares of the biotechnology company’s stock worth $113,464,000 after buying an additional 607,588 shares during the period. Waddell & Reed Financial Inc. bought a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth about $103,682,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Sarepta Therapeutics by 49.8% during the 3rd quarter. Wells Fargo & Company MN now owns 533,900 shares of the biotechnology company’s stock worth $86,231,000 after buying an additional 177,528 shares during the period. 89.84% of the stock is owned by institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.